Objective To analyze the efficacy of the combination of Compound Muniziqi Granules and Desloratadine Citrate Disodium Tablets in treatment of eczema.Methods A study was conducted on 100 patients with eczema admitted to Suzhou Ninth People's Hospital from March 2021 to March 2023.They were divided into control group and treatment group using a random envelope method,with 50 patients in each group.Patients of the control group were po administered with Desloratadine Citrate Disodium Tablets,1 tablets/time,once daily.Patients of the treatment group were po administered with Compound Muniziqi Granules on the basis of the control group,1 bag/time,3 times daily.Patients in both groups were treated for 7 d.The total effective rate,skin lesions,quality of life,immune function,and inflammatory factors were compared between two groups.Results The total effective rate(86.00%)of the treatment group was higher than 68.00%of the control group(P<0.05).After treatment,EASI score and pruritus degree score decreased significantly(P<0.05),and EASI score and pruritus degree score in the treatment group were lower than those in the control group(P<0.05).After treatment,the levels of CD3+and CD4+in both groups increased,while the levels of CD8+in both groups decreased(P<0.05).The levels of CD3+and CD4+in treatment group were higher than those in the control group,but the levels of CD8+in treatment group was lower than that in the control group.After treatment,the serum levels of IL-6 and TNF-α in both groups were decreased,while the serum levels of IL-10 in both groups were increased(P<0.05).The serum levels of IL-6 and TNF-α in the treatment group were lower than those in the control group,while the serum levels of IL-10 in the treatment group were higher than those in the control group(P<0.05).Conclusion Compound Munizizi Granules combined with Desloratadine Citrate Disodium Tablets can effectively promote the recovery of skin lesions in eczema patients,improve the quality of life,enhance immune function and reduce inflammation.